Skip to main content

What are you looking for?

Write the name, title or any keyword related to what you are looking for and select which content category it belongs to.

Year
2025
Títol Complet
Institutional framework agreement for technical and support services in developement of competitive proposals (excluding ERC proposals) (Lot 1) and development of competitive proposals (ERC proposals) (Lot 2) and support services in the post-award management of competitive projects (Lot 3) of the Fundació Hospital Universitari Vall Hebron - Institut de Recerca (VHIR)
Expedient
FRAMEWORK AGREEMENT FOR TECHNICAL AND SUPPORT SERV
Codi
24979135
Data publicació
Year
2025
Títol Complet
Contractació del servei d'assegurances de salut privada, a través del pla de compensació flexible, destinat a tot el personal de la Fundació Hospital Universitari Vall Hebron - Institut de Recerca (VHIR)
Expedient
ASSEGURANCES DE SALUT (PCF)
Codi
24979060
Data publicació

Professionals

Anika Pupak

I am a Local Research Coordinator at Barcelona site (Vall d’Hebron) of the European Spine Study Group, which I joined in 2023.

Professionals

Rucsanda Pinteac

Professionals

Juan Fernando Fuentes Cabrera

I'm a doctor specializing in Otorhinolaryngology and Head and Neck Surgery. Within the ENT department , I work in the head and neck section, with special interest in head and neck cancer and minimally invasive techniques such as robotic surgery, as well as benign pathology in this area. I have a

A phase 2, randomized, placebo-controlled, double-blind multiple ascending dose study in patients with cystic fibrosis carrying the 3849 +10 kb C->t mutation to evaluate the safety, tolerability, phamacokinetics and preliminary efficacy of SLP84

  • Protocol code: SPL84-002
  • EudraCT code: No aplica
  • Pathology: Malalties del sistema respiratori
  • Principal investigator:  Álvarez Fernandez, Antonio
  • Research group:  Pneumologia
  • Service: Pneumologia
  • Phase: Fase II
  • Recruiting: Open
  • Status: Iniciat

Contact Form

I have read and accept the data protection policy *.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Estudio fase IIb, aleatorizado, doble ciego, controlado con placeboy con comparador activo abierto para evaluar la eficacia, seguridad y tolerabilidad deAZD5004 en adultos con diabetes mellitus tipo 2

  • Protocol code: D7261C00001
  • EudraCT code: No aplica
  • Pathology: Malalties endocrines, nutricionals i metabòliques
  • Principal investigator:  Ciudin Mihai, Andreea
  • Research group:  Diabetis i metabolisme
  • Service: Endocrinologia
  • Phase: Phase II
  • Recruiting: Open
  • Status: Open

Contact Form

I have read and accept the data protection policy *.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

“Efficacy and safety of co administered cagrilintide and semaglutide(CagriSema) once weekly versus placebo in participants with type 2diabetes and painful diabetic peripheral neuropathy

  • Protocol code: NN9388-7864
  • EudraCT code: No aplica
  • Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
  • Principal investigator:  Ortiz Zuñiga, Angel Michael
  • Research group:  Diabetes and Metabolism
  • Service: Endocrinology
  • Phase: Phase II
  • Recruiting: Open
  • Status: Open

Contact Form

I have read and accept the data protection policy *.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Estudio de fase 3, aleatorizado, doble ciego y controlado con tratamiento activo para evaluar el cambio a una pauta semanal de islatravir/lenacapavir por vía oral en personas con VIH-1 con supresión virológica bajo tratamiento con bictegravir/emtricitabina/tenofovir (B/F/TAF)

  • Protocol code: GS-US-563-5925
  • EudraCT code: No aplica
  • Pathology: Certes malalties infeccioses i parasitàries
  • Principal investigator:  Curran Fàbregas, Adria
  • Research group:  Infectious Diseases
  • Service: Infeccioses
  • Phase: Fase III
  • Recruiting: Open
  • Status: Open

Contact Form

I have read and accept the data protection policy *.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

' Efficacy and safety of co-administered cagrilintide and semaglutide(CagriSema 2.4 mg/2.4 mg) once-weekly versus semaglutide 2.4 mg,cagrilintide 2.4 mg and placebo in people with chronic kidneydisease and type 2 diabetes living with overweight or obesity.'

  • Protocol code: NN9388-7700
  • EudraCT code: No aplica
  • Pathology: Symptoms, signs, and abnormal clinical and laboratory findings, not elsewhere classified
  • Principal investigator:  Soler Romeo, Maria Jose
  • Research group:  Nefrologia i trasplantament renal
  • Service: Nefrologia
  • Phase: Phase II
  • Recruiting: Open
  • Status: Open

Contact Form

I have read and accept the data protection policy *.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Estudio de fase III, aleatorizado, doble ciego, controlado con placebo y multicéntrico para evaluar la eficacia y la seguridad de anifrolumab en adultos con lupus eritematoso cutáneo subagudo o crónico que son resistentes o intolerantes al tratamiento antipalúdico

  • Protocol code: D346BC00001
  • EudraCT code: No aplica
  • Pathology: Symptoms, signs, and abnormal clinical and laboratory findings, not elsewhere classified
  • Principal investigator:  Cortes Hernandez, Josefina
  • Research group:  Reumatologia
  • Service: Reumatologia
  • Phase: Phase II
  • Recruiting: Closed
  • Status: Open

Contact Form

I have read and accept the data protection policy *.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician’s choice chemotherapy compared to trastuzumab in combination with physician’s choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous trastuzumab deruxtecan treatment.

Contact Form

I have read and accept the data protection policy *.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.

Estudio de fase 2, adaptivo, aleatorizado, abierto y con control activo ciego para el evaluador para valorar la eficacia y la seguridad de rapcabtagene autoleucel frente al tratamiento de referencia en pacientes que padecen lupus eritematoso sistémico con nefritis lúpica refractaria activa.

  • Protocol code: CYTB323J12201
  • EudraCT code: No aplica
  • Pathology: Symptoms, signs, and abnormal clinical and laboratory findings, not elsewhere classified
  • Principal investigator:  Cortes Hernandez, Josefina
  • Research group:  Rheumatology
  • Service: Rheumatology
  • Phase: Phase II
  • Recruiting: Closed
  • Status: Open

Contact Form

I have read and accept the data protection policy *.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.
Year
2025
Títol Complet
Serveis professionals i d’assessoria legal en herències, successions, donació inter vius de béns, administració i liquidació de béns testamentaris, inclòs la venda d’immobles titularitat del VHIR, dividit en dos (2) lots, destinat a la Unitat de Serveis Jurídics de la Fundació Hospital Universitari Vall Hebron - Institut de Recerca (VHIR).
Expedient
SERVEIS EN GESTIÓ D’HERÈNCIES
Codi
24978236
Data publicació
Year
2025
Títol Complet
Servicio de soluciones tecnológicas con REDCap y soporte técnico para análisis estadísticos y manejo de datos, a cargo del Grupo de investigación en Cáncer y Enfermedades Hematológicas Infantiles, línea de investigación en Anemias Raras, de la Fundació Hospital Universitari Vall Hebron - Institut de Recerca (VHIR).
Expedient
SOLUCIONES TECNOLÓGICAS CON REDCAP
Codi
24978160
Data publicació
Year
2025
Títol Complet
Servicio de análisis transcripcional de célula individual (single cell analysis) mediante la plataforma COSMX (nanostring), a cargo del Proyecto PI23/01041, destinado al Grupo de Tumores Torácicos de la Fundació Hospital Universitari Vall Hebron - Institut de Recerca (VHIR).
Expedient
ANALISIS TRANSCRIPCIONAL CÉLULA INDIVIDUAL (PI23/0
Codi
24978159
Data publicació

Professionals

Hugo Ramos Abellan